This procedure has a name. It is called inequity.
In the Philippines, where tuberculosis strikes nearly five times the global average, a public health specialist has named the quiet mechanism behind the country's persistent epidemic: a fragmented diagnostic system that forces the sick to choose between their health and their livelihood. Dr. Rugaiya Calapis, speaking at a Bangkok symposium in July 2026, proposed that integrated multi-disease testing—drawing multiple diagnoses from a single specimen—could close the gap between diagnosis and treatment that causes patients to vanish from care. Her argument is not merely technical; it is a reckoning with the way systems, designed to heal, can be built in ways that abandon the most vulnerable at the very moment they seek help.
- The Philippines carries the third-highest TB burden on earth—625 cases per 100,000 people—yet its diagnostic system is fragmented enough to drive patients away before treatment even begins.
- Patients like Juan, a 32-year-old who tested positive for TB, never return for mandatory follow-up tests because each visit means another day of lost wages, turning a treatable disease into an ongoing transmission event.
- A critical blind spot compounds the crisis: Philippine labs routinely test for rifampicin resistance but not isoniazid resistance, meaning some patients spend months on drugs their TB has already learned to defeat, accelerating drug-resistant strains.
- Dr. Calapis is advocating for integrated laboratory platforms that test a single specimen for multiple pathogens at once, collapsing multiple visits into one and closing the diagnostic gaps that cause treatment to fail.
- The proposal is gaining attention as a structural correction—not a cure—that could slow drug-resistant TB transmission, reduce mortality, and keep patients like Juan connected to the care they need.
Rugaiya Calapis tells the story of Juan, a 32-year-old patient who came in coughing and losing weight, tested positive for tuberculosis, and then disappeared. Protocol required a second visit for an HIV test—TB and HIV frequently co-occur—but Juan had already sacrificed one day's wages for the first appointment. He could not afford another. His TB went untreated. The disease kept spreading. The system recorded it as procedure.
This is not an exception. The Philippines carries the third-heaviest TB burden on earth—625 cases per 100,000 people, nearly five times the global average—and yet its diagnostic infrastructure is built in a way that punishes patients for seeking care. Calapis, who chairs the Department of Health's TB Medical Advisory Council for the National Capital Region South, has spent her career watching this pattern repeat.
At a medical symposium in Bangkok in July 2026, she proposed a different architecture: integrated testing, in which a single specimen is run through a common molecular platform capable of detecting multiple diseases at once. One visit. One sample. Results returned to the physician. Treatment initiated before the patient has reason to give up. The logic is straightforward, but the current system—labyrinthine, fragmented, and scattered across separate services with separate schedules and locations—resists it at every turn.
Calapis also identified a specific and consequential blind spot: Philippine laboratories test routinely for resistance to rifampicin, one of the two main first-line TB antibiotics, but far less often for resistance to isoniazid, the other. Patients prescribed drugs their TB has already learned to resist spend months on ineffective treatment. The bacteria survive, adapt, and become harder to kill. What begins as a manageable infection can evolve into a multi-drug-resistant strain capable of spreading through households and crowded commutes.
Closing that single diagnostic gap—making isoniazid resistance testing as routine as rifampicin testing—would redirect the entire clinical course for many patients. Combined with integrated testing that removes the logistical barriers driving abandonment, the framework Calapis describes is not a cure but a correction: the kind of infrastructural repair that, in public health, separates a disease that is managed from one that runs unchecked.
Rugaiya Calapis watched her patient—a 32-year-old man she calls Juan in her telling—disappear after his first diagnosis. He had come in coughing, losing weight, and she ordered a sputum test. The results came back positive for tuberculosis. Protocol demanded a second test, this one for HIV, which often travels alongside TB in the body. But Juan never returned. He had already taken an unpaid day off work for the first appointment. A second trip meant another lost wage, another disruption. His TB went untreated. The virus continued to spread. And the system, Calapis said, simply shrugged and called it procedure.
This is not an edge case. It is the daily machinery of public health in countries where tuberculosis runs deep. The Philippines carries the third-heaviest TB burden on earth—625 cases per 100,000 people, nearly five times the global average of 131 per 100,000. Only India and Indonesia carry more. And yet the system that is supposed to catch and treat these cases is fragmented, inefficient, and built in a way that punishes the very people it aims to help. Calapis, who chairs the Department of Health's TB Medical Advisory Council for the National Capital Region South, has spent her career watching patients like Juan slip through the cracks.
At a medical symposium in Bangkok in July, she laid out a different vision. Instead of sending patients on a pilgrimage through separate laboratory systems—one test for TB, another for HIV, another for HPV or other infections—what if a single specimen could be tested for multiple diseases at once? A patient provides one sample. It travels to a central laboratory. The lab runs it through a common molecular platform designed to detect as many pathogens as the science allows. Results come back to the doctor. Treatment begins. One visit. One lost wage, if any. One chance to interrupt the chain of transmission before it spreads further.
The logic is almost embarrassingly simple, yet the current system resists it. Calapis described the existing architecture as labyrinthine and fragmented—a word choice that captures both the complexity and the waste. Patients navigate separate services, each with its own scheduling, its own location, its own administrative friction. The cumulative burden is enough to break the link between diagnosis and treatment. And in TB, that link is everything. A patient who knows they are sick but cannot afford to keep returning becomes a vector, spreading the disease to family, to coworkers, to strangers on a crowded bus.
But there is another layer to this problem, one that Calapis emphasized with particular force. The Philippines has a specific diagnostic blind spot: isoniazid resistance. Isoniazid is one of the two main antibiotics used in first-line TB treatment. Yet Philippine laboratories test far more frequently for resistance to rifampicin, the other first-line drug. This gap means that some patients are prescribed medications their TB has already learned to resist. They take the drugs for months. The bacteria survive. The disease progresses. The patient's body develops resistance to additional drugs. What began as a treatable infection becomes a multi-drug-resistant strain, far harder to kill and far more likely to spread.
Closing this single diagnostic gap—ensuring that labs test for isoniazid resistance as routinely as they test for rifampicin resistance—would reshape the entire trajectory of care. Patients would receive the right treatment from the start, not months of ineffective drugs followed by a course correction. The spread of drug-resistant strains would slow. Mortality would fall. Transmission would drop. Calapis was careful not to oversell this as a minor tweak. She called it a fundamental correction, a redirection of the clinical course itself.
The integrated testing framework addresses both problems at once: it reduces the friction that causes patients to abandon treatment, and it closes the diagnostic gaps that cause treatment to fail even when patients do return. It is not a cure. It is infrastructure. But infrastructure, in public health, is often the difference between a disease that is managed and a disease that runs wild. In a country where TB infects 625 people per 100,000, where patients like Juan are making impossible choices between their health and their wages, infrastructure is everything.
Notable Quotes
Instead of navigating labyrinthine, fragmented services, patients experience a more coordinated pathway that reduces waste, minimizes lost wages, and increases the likelihood of linkage to treatment.— Rugaiya Calapis, TB specialist and chair of DOH-NCR South TB Medical Advisory Council
Closing just this isoniazid resistance testing gap changes the entire trajectory of care. It means the right treatment, right away, instead of months of ineffective first-line treatment.— Rugaiya Calapis
The Hearth Conversation Another angle on the story
Why does Juan not come back? Is it just the money?
It's the money, yes, but it's also the time, the disruption, the fact that he has to trust the system twice when the system has already asked so much of him. One unpaid day off is already a crisis for someone living paycheck to paycheck. Two visits means two crises.
And the system knows this?
The system knows it. Calapis is saying that explicitly. She's saying we call this procedure, but it's actually inequity. We've built a system that works fine for people with flexibility and resources, and it breaks for everyone else.
So the integrated testing—that solves the logistics problem. But what about the isoniazid resistance gap? That seems like a different issue entirely.
It is different, but it's connected. Both are about fragmentation. One is fragmentation in space—multiple locations, multiple visits. The other is fragmentation in knowledge—we test for some resistances but not others, so we're flying blind on part of the picture. Integrated testing addresses both.
Does it actually save money for the patient?
Yes. One specimen, one trip, one lost wage instead of multiple. But more importantly, it saves money for the system by preventing treatment failure, by catching drug resistance early, by stopping the spread of harder-to-treat strains. The patient saves money. The public health system saves money. Everyone wins except the fragmentation itself.
What happens if we don't do this?
Juan's TB doesn't get treated. He spreads it. Someone else gets infected. That person might develop drug-resistant TB because the system missed something in the diagnostic process. The disease gets harder to treat, more expensive to treat, more likely to be fatal. The burden on the country gets heavier, not lighter.